Source: PR Newswire

Press Release: Sitryx : Sitryx Therapeutics Announces Presentation at the Stifel 2022 Healthcare Conference

OXFORD, UK, Nov. 10, 2022 /PRNewswire/ -- Sitryx Therapeutics Ltd (the "Company"), a biopharmaceutical company pioneering the field of immunometabolism, today announced that the Company will participate in the Stifel 2022 Healthcare Conference, taking place November 15-16, 2022 in New...

Read full article »

Sitryx's Competitors | Sitryx's News | Sitryx's Financials

Followers on Owler

Est. Annual Revenue

$100K-5.0M

Est. Employees

1-25

CEO

Neil Weir

CEO Approval Rating

86/100

Sitryx is an England-based biopharmaceutical company that researches and develops immune cell metabolism therapies for the treatment of chronic autoimmune diseases and cancer.